Lymphocyte predominant Hodgkin Disease: Clinico-pathologic features and results of treatment—The pediatric oncology group experience

✍ Scribed by Karayalcin, Gungor; Behm, Fred G.; Gieser, Peter W.; Kung, Faith; Weiner, Michael; Tebbi, Cameron K.; Ferree, Carolyn; Marcus, Robert; Constine, Louis; Mendenhall, Nancy P.; Chauvenet, Allen; Murphy, Sharon B.

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 47 KB
• Volume: 29
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/(sici)1096-911x(199712)29:6<519::aid-mpo1>3.0.co;2-n

✦ Synopsis

In this report, the Pediatric Oncology Group (POG) experience with lymphocyte predominant Hodgkin Disease (LPHD) in children is reviewed.

Materials and Methods. From 1984From -1993, the POG conducted 3 clinical trials for advanced stage HD and 2 for early stage HD. There were 26 cases of LPHD in 613 patients in these trials. Patients' ages ranged from 3.1-17.8 years (mean of 12.9 years). There was a marked male predominance.

Results. Histologic subtypes were 17 nodular, 8 diffuse pattern; 1 was indeterminant. The sites involved at diagnosis were primarily the peripheral lymph nodes. Fourteen patients had stage (S) I disease; 9 had SII; 3 had SIII; there was no SIV disease. Only 4 of 26 patients had B symptoms. All 26 patients achieved complete remission, 10 with radiotherapy, 6 with chemotherapy and 10 with combined modality therapy. Treatment was not uniform since patients were registered on different protocols. Event-free survival after 5 years was 86.5 percent. Two patients developed and succumbed to large cell, T-cell type, non-Hodgkin lymphoma (NHL).

Conclusions. Optimal treatment for LPHD should focus on efforts to limit the risk of second malignancy. Med.